Correction to “Mitogen‐Activated Protein Kinase Inhibition Augments the T Cell Response Against HOXB7‐Expressing Tumor Through Human Leukocyte Antigen Upregulation”
Abstract
Genes, proteins, chemicals, diseases, species, mutations and cell lines named across the full text — each resolved to its canonical identifier and authoritative record.
Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
Taxonomy
TopicsCancer Immunotherapy and Biomarkers · CAR-T cell therapy research · Neutrophil, Myeloperoxidase and Oxidative Mechanisms
Komatsuda H, Wakisaka R, Kono M, et al. Mitogen‐activated protein kinase inhibition augments the T cell response against HOXB7‐expressing tumor through human leukocyte antigen upregulation. Cancer Sci. 2023;114:399–409. doi: 10.1111/cas.15619
In the above article, there were errors in the following texts:
From Section 3.2:
Based on computer‐based algorithms, HOXB7 8‐25 (PLLLKLLKSVGAQKD) was selected as a potential candidate for eliciting antigen‐specific HTL responses.
The correct text should be as follows:
Based on computer‐based algorithms, HOXB7 8‐25 (NTLFSKYPASSSVFATGA) was selected as a potential candidate for eliciting antigen‐specific HTL responses.
From Section 4:
As HOXB7 18‐26 (SSVFAPGAF) might bind to HLA‐A*26:01 in in silico analysis, the elongation of HOXB7 8‐25 to HOXB7 8‐26 would improve the antigenicity of the peptide by inducing both HTLs and CTLs.
The correct text should be as follows:
As HOXB7 18‐26 (SSVFATGAF) might bind to HLA‐A*26:01 in in silico analysis, the elongation of HOXB7 8‐25 to HOXB7 8‐26 would improve the antigenicity of the peptide by inducing both HTLs and CTLs.
We apologize for these errors.